Which country is Delamanid from?

Delamanid(Delamanid) is an anti-tuberculosis drug with the trade name Deltyba, developed by Otsuka Pharmaceutical Co., Ltd. of Japan. The oral bioavailability of delamanid in humans is estimated to be 25%-47%, increasing significantly with increasing amounts of high-fat meals. Delamanid is highly protein bound (99.5%), which helps provide a long half-life of 30-38 hours.

Delamanid is a dihydronitroimidazole derivative. Acts by inhibiting the synthesis of mycobacterial cell wall components methoxymycolic acid and ketomycolic acid. Delamanidis a prodrug activated by deazoflavin-dependent nitroreductase(Rv3547). Reactive intermediate metabolites formed betweendelamaniand denitroimidazole derivatives are thought to play an important role in the inhibition of mycolic acid production.

In in vitro studies,delamanishowed enhanced antibacterial activity against drug-susceptible and drug-resistant strains of Mycobacterium tuberculosis. Minimum inhibitory concentrations were observed in the very low range of 0.006-0.024 μg/ml. Post-antibiotic effects on intracellular organisms after pulse therapy have been demonstrated and are comparable to rifampicin. There is no cross-resistance or antagonism with first-line anti-tuberculosis drugs. Delamanidhas no mutagenicity in bacterial reverse mutation tests. High efficacy in rapid eradication of Mycobacterium tuberculosis was demonstrated in experimental mouse models. If you want to get more high-quality information, you can contact Yaode, and Yaode will do its best to help you learn more about high-quality overseas drugs.